Company / Cash & Equivalents
Alaunos Therapeutics, Inc. Cash & Equivalents History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.4M
FY2025
5-year range
$1.1M / $76.1M
FY2021-FY2025
Trend
+26.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 4 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -58.7%.
Declined from $6M to $1M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -67.1%
- 5-Year CAGR
- -58.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -58.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 26.9% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | +26.9% |
| FY2024 | $1.1M | -82.0% |
| FY2023 | $6.1M | -84.5% |
| FY2022 | $39.1M | -48.6% |
| FY2021 | $76.1M | -33.9% |
| FY2020 | $115.1M | +44.3% |
| FY2019 | $79.7M | +12.4% |
| FY2018 | $70.9M | -32.2% |
| FY2013 | $104.7M | +73.4% |
| FY2012 | $60.4M | +23.7% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026